We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Mammography Software Company Expands Its Presence in Chinese Market

By MedImaging International staff writers
Posted on 27 Apr 2014
Print article
A mammography product line provides quality images with superior visibility of the parenchyma and dense breast tissue. This helps clinicians more effectively diagnose breast cancer patients while improving patient care.

At the 71st China International Medical Equipment Fair (CMEF), held in Shenzhen (China) during April 17–20, 2014, ContextVision (Stockholm, Sweden) demonstrated its US PLUSView Family and GOPView Mammo2 image quality software, the latest additions to its multimodality product range.

The USPLUSView range of products includes features four packages for women’s health, general imaging, cardiovascular and point of care. Each package offers efficient line connectivity, speckle reduction, edge enhancement and higher grayscale contrast. These features make it easier for medical professionals to detect lesions and provide sharper edges, thereby providing greater diagnostic confidence. The packages are adaptable for all hardware platforms.

GOPView Mammo2 is the latest upgrade to ContextVision’s mammography product line. ContextVision has been immersed in the Chinese market for the past10 years and recognizes the increasing demand for quality imaging software and expertise as the industry rapidly expands in this geography. To meet this demand, ContextVision has expanded its presence in Beijing with an application specialist. The company strengthens its relationship with this placement and support with present and future original equipment manufacturer (OEM) customers.

“We’ve seen increased interest for our products in the dynamic Chinese market and in order to effectively manage this growth, we reallocated expert resources to our Beijing office,” said Anita Tollstadius, CEO of ContextVision. “This will enable collaboration with our current OEMs and partnership with future OEM customers, in which we will be able to provide a high level of support.”

CMEF is the largest exhibition of medical equipment, products and services in the Asia-Pacific region attracting nearly 2,000 exhibitors and more than 60,000 visitors from more than 100 countries and regions. CMEF is Asia’s most comprehensive event, offering the best resources for direct buyers, agents, distributors, partners and government and hospital management staff for engagement with the Chinese market.

ContextVision is a provider of image enhancement software, with the versatile GOP technology at its core. ContextVision offer the latest software and expertise within ultrasound, X-ray, magnetic resonance imaging (MRI), mammography, interventional radiology, and computed tomography (CT).

Related Links:

ContextVision


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Ultrasound Doppler System
Doppler BT-200
New
Enterprise Imaging & Reporting Solution
Syngo Carbon
Thyroid Shield
Standard Thyroid Shield

Print article
Radcal

Channels

MRI

view channel
Image: The emerging role of MRI alongside PSA testing is redefining prostate cancer diagnostics (Photo courtesy of 123RF)

Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients

Prostate cancer is a leading health concern globally, consistently being one of the most common types of cancer among men and a major cause of cancer-related deaths. In the United States, it is the most... Read more

Nuclear Medicine

view channel
Image: The new SPECT/CT technique demonstrated impressive biomarker identification (Journal of Nuclear Medicine: doi.org/10.2967/jnumed.123.267189)

New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access

The development of lead-212 (212Pb)-PSMA–based targeted alpha therapy (TAT) is garnering significant interest in treating patients with metastatic castration-resistant prostate cancer. The imaging of 212Pb,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.